SCHEMBL10596294

SCHEMBL10596294

CC(C)CNC(=O)Nc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
EPHX1 P07099 5/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TP53 P04637 2/20 0.57
TSHR P16473 1/20 0.57
EPHX2 P34913 1/20 0.57
CDK9 P50750 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 2/20 0.54
MEN1 O00255 2/20 0.54
HPGD P15428 2/20 0.54
HTT P42858 1/20 0.54
MAPT P10636 1/20 0.53
TAAR1 Q96RJ0 1/20 0.52
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7749716 0.87 EPHX1 (0.55) LMNAEPHX1SMN1; SMN2TP53TSHR
SCHEMBL17596717 0.87 EPHX1 (0.55) LMNAEPHX1SMN1; SMN2TP53TSHR
SCHEMBL17596716 0.87 EPHX1 (0.55) LMNAEPHX1SMN1; SMN2TP53TSHR
SCHEMBL11647644 0.86 EPHX1 (0.53) EPHX1SMN1; SMN2TP53TSHREPHX2
SCHEMBL11583833 0.86 EPHX1 (0.53) LMNAEPHX1SMN1; SMN2TP53TSHR
SCHEMBL8282413 0.83 EPHX1 (0.50) LMNAEPHX1SMN1; SMN2TP53TSHR
SCHEMBL11586099 0.82 EPHX1 (0.55) EPHX1SMN1; SMN2TP53TSHREPHX2
SCHEMBL22535071 0.82 RAB9A (0.59) LMNASMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL27861126 0.82 RAB9A (0.60) LMNAEPHX1SMN1; SMN2EPHX2RAB9A
SCHEMBL5243485 0.82 LMNA (0.64) LMNASMN1; SMN2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20220184185-A1 MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS MODERNATX, INC. 2022-06-16 US disclosed
US-4888321-A SUBBING AND RECORDING LAYERS EACH CONTAINING HEAT FUSIBLE MATERIAL WITH DEFINED MELTING POINT FUJI PHOTO FILM CO., LTD. (JP) 1989-12-19 US disclosed
US-4533929-A ANIONIC SURFACTANTS AS ANTIFOGGING AGENTS; DIETHYLHEXYL SULFOSUCCINATE FUJI PHOTO FILM CO., LTD. (JP) 1985-08-06 US disclosed
US-4520377-A COLOR FORMING LAYER COMO/SED OF ELECTRON DONATING COLORLESS DYE, ELECTRON ACCEPTING COMPOUND, NAPHTHOL UREA AND/OR URETHANE DERIVATIVE FUJI PHOTO FILM CO., LTD. (JP) 1985-05-28 US disclosed
US-4401717-A CONTAINING A CHROMOGEN, A PHENOL LAND A UREA OR CARBAMATE; THERMOGRAPHY FUJI PHOTO FILM CO., LTD. (JP) 1983-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 LMNA 1896/4885EPHX1 4597/4885SMN1; SMN2 3828/4885
US-20220184185-A1 MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS GAA, GBA1, GBA2 LMNA 1299/4885EPHX1 2341/4885SMN1; SMN2 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.